journal article·2000-01

Lactic acid-stabilised albumin for microsphere formulation and biomedical coatings

A.G.A. Coombes, V. Breeze, Wu Lin, T. Gray, K.G. Parker, T. Parker

Biomaterials· Volume 22· Issue 1
Publisher page

Abstract

Microspheres of ovalbumin (OVA) ranging from 1 to 15 microm were prepared by emulsifying an aqueous solution of albumin in soya oil at room temperature then raising the temperature to 45 degrees C for 30 min, prior to harvesting of the microspheres. Production of OVA nanospheres with size less than 500 nm was achieved by desolvation from aqueous albumin solutions using acetone. In both cases, lactic acid was added to the starting albumin solution to stabilise the resulting particles. Utilisation of an endogenous substance avoids the use of chemical crosslinking agents such as glutaraldehyde and associated toxicological concerns. Protein coating of knitted Dacron vascular grafts was performed by impregnation of the textile structure with lactic acid-stabilised ovalbumin nanospheres thereby providing a surface potentially resistant to blood platelet adhesion but conducive to endothelialisation. Protein release testing carried out in PBS at 37 degrees C revealed that approximately 60% of the original albumin coating was retained by the Dacron graft material after 4 days and remained at this level for upto 4 weeks. Apart from the formulation of albumin microspheres for drug delivery, diagnostic applications and coating of biomedical textiles, the process of albumin stabilisation using lactic acid may be usefully applied to improve protein immobilisation on a wide range of biomaterial surfaces.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Protein purification and stability

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (25)

Show source-provided references
1. Tomlinson E, Burger JJ. Monolithic albumin particles as drug carriers. In Illum L, Davis SS, editors. Polymers in controlled drug delivery. Bristol, UK: IOP Publishing, 1987. p. 25–48.
2. An albumin-coated polyester arterial graft: in vivo assessment of biocompatibility and healing characteristics10.1016/0142-9612(96)80749-6 ↗
3. Characteristics of polyester arterial grafts coated with albumin: the role and importance of the cross-linking chemicals10.1159/000128736 ↗
4. Albumin microspheres and microcapsules: methodology of manufacturing techniques10.1016/0168-3659(90)90149-N ↗
5. Spray dried albumin microspheres for the intra-articular delivery of dexamethasone10.3109/02652049409034262 ↗
6. Preparation of human serum albumin microspheres by a novel acetone-heat denaturation method10.3109/02652049409034257 ↗
7. Preparation of sub-100nm human serum albumin nanospheres using a pH-coacervation method10.3109/10611869308996081 ↗
8. Endothelial cell compatibility testing of various prosthetic surfaces10.1007/BF00213139 ↗
9. Albumin immobilised polyurethane and its blood compatibility10.1097/00002480-199207000-00116 ↗
10. Influence of endogenous albumin binding on blood-material interactions10.1111/j.1749-6632.1987.tb33032.x ↗
11. Influence of some plasma proteins on in vitro bacterial adherence to PTFE and Dacron vascular prostheses10.1111/j.1699-0463.1993.tb00203.x ↗
12. Albumin impregnated vascular grafts: albumin resorption and tissue reactions
13. Study on the prevention of surface-induced platelet activation by albumin coating10.1163/156856292X00196 ↗
14. Heat denatured albumin-coated Dacron grafts: physical characteristics and in vivo performance10.1067/mva.1986.avs0040136 ↗
15. Healing parameters of a new albumin-coated knitted Dacron graft10.1055/s-2007-1022711 ↗
16. Comparative in vivo study on the healing qualities of four different presealed vascular prostheses10.1067/mva.1993.39245 ↗
17. Peters T. Serum albumin. Adv Protein Chem 1985; 37:161–236.10.1016/S0065-3233(08)60065-0 ↗
18. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen10.1016/S0264-410X(96)00077-1 ↗
19. Release of human serum albumin from poly(lactide-co-glycolide) microspheres10.1023/A:1015948829632 ↗
20. Gombotz WR, Pettitt DK. Biodegradable polymers for protein and peptide drug delivery. Bioconjugate Chem 1995;6:332–51.10.1021/bc00034a002 ↗
21. The distribution of protein associated with poly(dl-lactide co-glycolide) microparticles and its degradation in simulated body fluids10.1016/S0168-3659(97)00145-4 ↗
22. Cappello J. Synthetically designed protein–polymer biomaterials. In: Park K, editor. Controlled drug delivery. Challenges and strategies. Washington DC: American Chemical Society, 1997. p. 439–53 [Chapter 21].
23. The development of stable protein formulations: a close look at protein aggregation, deamidation and oxidation
24. Schwendeman SP, Costantino HR, Gupta R, Langer R. Peptide, protein and vaccine delivery from implantable polymeric systems. In: Park K, editor. Controlled drug delivery. Challenges and strategies. Washington, DC: American Chemical Society, 1997. p. 229–67 [Chapter 12].
25. Endothelial seeding of compliant polyurethane vascular graft material10.1002/bjs.1800810908 ↗